Start-Up Claims to Use A.I.-Created Viruses to Treat a Patient - The New York Times

“A New York Times article reports that a biotech startup claims to have used AI-generated viruses to treat a patient, marking a first in applying machine learning to viral vector design. The approach, which involves engineering viral genomes with advanced algorithms, is still experimental and has raised safety and regulatory concerns, prompting the FDA to begin a review. In the U.S., this could accelerate the adoption of AI-driven therapeutics, potentially lowering drug development costs and expanding treatment options for rare diseases, while also raising ethical questions about virus manipulation and biosecurity. Expert Analysis: This development signals a paradigm shift in precision medicine, where AI can design bespoke viral vectors tailored to individual patients. If regulatory hurdles are cleared, the U.S. biotech sector could see a surge in venture capital and a new wave of AI-enabled therapeutics, reshaping the competitive landscape and potentially driving down costs for patients.”